SELLAS Life Sciences raises $25M in registered direct offering of common stock and warrants

SELLAS Life Sciences Group, Inc.

19,685,040 shares (or pre-funded warrants) plus 19,685,040 common warrants at $1.27 combined price.
Warrants exercisable at $1.20 per share, expire 5 years from issuance.
Gross proceeds ~$25M; net proceeds for working capital and general corporate purposes.
Offering priced at-the-market under Nasdaq rules; expected to close Jan 29, 2025.
Single healthcare-focused institutional investor; A.G.P. and Maxim as placement agents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.